Selank
Neuropeptides
£30.00per vial
Selank is a synthetic heptapeptide analogue of tuftsin, catalogued for GABAergic and neuroimmune signalling research. The sequence TKPRPGP appends Pro-Gly-Pro to the native tuftsin tetrapeptide, extending stability enough for controlled experimental work.
For laboratory research only. Not for human consumption. No medical claims. This product is not intended to diagnose, treat, cure, or prevent any disease.
This vial is sealed for the protection of health and hygiene. Under regulation 28(1)(e) of the Consumer Contracts (Information, Cancellation and Additional Charges) Regulations 2013, the 14-day right to cancel is lost for this item once that seal is broken. While the seal is intact the right applies in full.
Selank cannot be listed to research users in Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. Verify local eligibility before ordering.
Listed
- Molecular weight
- 751.9 g/mol
- Sequence
- TKPRPGP
- Presentation
- Pre-mixed liquid, 3ml vial
For laboratory research only. Not for human consumption. No medical claims.
- UK DISPATCH
- TRACKED SHIPPING
- COA PER BATCH
- SECURE PAYMENT
§01Compound Profile
Every batch is independently analysed by HPLC and mass spectrometry before it is listed, and the Certificate of Analysis for that batch is published in full, including the measured purity figure for that batch.
HPLC
Purity by chromatography
ANALYSED
MASS SPECTROMETRY
Identity confirmation
ANALYSED
PUBLIC COA
Every batch number resolves to its Certificate of Analysis
DOCUMENTED
§02The Science
Published constants and presentation for Selank, as catalogued.
Every figure in this list is a published constant or a presentation fact. None of it is an analytical result: the measured figures live on the Certificate of Analysis for the batch.
- Molecular weight
- 751.9 g/mol
- Sequence
- TKPRPGP
- Presentation
- Pre-mixed liquid, 3ml vial
- Batch reference
- SL5610
Molecular weight source: PubChem CID 11765600.
§03Certificate of Analysis
Every batch is independently analysed by HPLC and mass spectrometry before it is listed, and the Certificate of Analysis for that batch is published in full, including the measured purity figure for that batch.
| PARAMETER | METHOD | RESULT |
|---|---|---|
| Purity | HPLC | 97.8% |
| Identity | Mass spectrometry | Confirmed |
SL5610 · 2026-07-04
§04Compound details
Selank is built from tuftsin, a tetrapeptide fragment of the immunoglobulin G heavy chain with documented immunomodulatory activity. The same C-terminal Pro-Gly-Pro extension used in Semax is applied here, producing the heptapeptide TKPRPGP. The extension is a stability modification rather than a functional one, and it is why the compound is workable in laboratory conditions where native tuftsin is not.
Two pathways account for most of the published work. The first is GABAergic: preclinical studies examine expression of GABA-A receptor subunits in hippocampal and cortical tissue following administration, treating the compound as a modulator of receptor expression rather than a direct receptor ligand. The second is enkephalinergic, where the research question is inhibition of enkephalin-degrading enzymes and the consequent extension of endogenous enkephalin half-life in plasma and tissue.
Its tuftsin lineage also places it in neuroimmune research. Studies examine interleukin-6 and interferon-gamma expression alongside the central signalling measures, which is unusual: the compound is one of a small number used to probe where immune signalling and neurotransmitter regulation intersect in the same model. Behavioural work in animal subjects covers stress-reactivity and anxiety-like paradigms. No therapeutic, diagnostic, or clinical conclusion is drawn from any study referenced above, and none should be inferred.
Selank is listed as a pre-mixed liquid in a sealed 3ml vial, at 10mg. There is no reconstitution step for the research user to perform, and no lyophilised powder to handle.
Every batch is independently analysed before it is listed. Purity is measured by high-performance liquid chromatography. Identity is confirmed by mass spectrometry, which is the method that distinguishes the full heptapeptide from the tuftsin tetrapeptide it derives from, since the two are chemically related and a purity figure alone would not separate them. Those are the two analytical methods used, and no other method is claimed.
Each vial carries a batch number that resolves to the public Certificate of Analysis for its batch, reporting the compound, the lot reference, the HPLC result, the mass-spectrometry result, the analysis date, and the laboratory that ran it.
Research Use Only
Selank is catalogued strictly for in-vitro laboratory research. It is not for human consumption, veterinary use, or therapeutic, diagnostic or clinical application. It is not supplied as a medicinal product and it is not licensed by the MHRA.
Not a Medical Product
None of the compounds listed on this site are medicinal products, nor should they be marketed, described or used as such. No medical claims are made about Selank. Nothing on this page is medical, veterinary or scientific advice, and no guidance on preparation, administration or quantity is provided or will be provided on request.
Compliance and Responsibility
The research user is responsible for ensuring compliance with all laws and regulations governing the receipt, handling, storage, use and disposal of research chemicals in their jurisdiction, and for applying appropriate control measures under the Control of Substances Hazardous to Health Regulations 2002 or the equivalent local regime.
Analytical Scope
Analytical results published for Selank relate solely to the batch identified on the Certificate of Analysis. Two methods are used: high-performance liquid chromatography and mass spectrometry. No other analysis is performed or implied. Results for one batch do not warrant any other batch.
Jurisdiction Notice
Selank cannot be listed to research users in the following jurisdictions: Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. It is the research user's responsibility to verify local eligibility before placing an order. Where an order is placed for a jurisdiction in which the compound cannot be listed, the order will be cancelled and refunded in full.
Research Context
Selank is built from tuftsin, a tetrapeptide fragment of the immunoglobulin G heavy chain with documented immunomodulatory activity. The same C-terminal Pro-Gly-Pro extension used in Semax is applied here, producing the heptapeptide TKPRPGP. The extension is a stability modification rather than a functional one, and it is why the compound is workable in laboratory conditions where native tuftsin is not.
Two pathways account for most of the published work. The first is GABAergic: preclinical studies examine expression of GABA-A receptor subunits in hippocampal and cortical tissue following administration, treating the compound as a modulator of receptor expression rather than a direct receptor ligand. The second is enkephalinergic, where the research question is inhibition of enkephalin-degrading enzymes and the consequent extension of endogenous enkephalin half-life in plasma and tissue.
Its tuftsin lineage also places it in neuroimmune research. Studies examine interleukin-6 and interferon-gamma expression alongside the central signalling measures, which is unusual: the compound is one of a small number used to probe where immune signalling and neurotransmitter regulation intersect in the same model. Behavioural work in animal subjects covers stress-reactivity and anxiety-like paradigms. No therapeutic, diagnostic, or clinical conclusion is drawn from any study referenced above, and none should be inferred.
Analysis and Documentation
Selank is listed as a pre-mixed liquid in a sealed 3ml vial, at 10mg. There is no reconstitution step for the research user to perform, and no lyophilised powder to handle.
Every batch is independently analysed before it is listed. Purity is measured by high-performance liquid chromatography. Identity is confirmed by mass spectrometry, which is the method that distinguishes the full heptapeptide from the tuftsin tetrapeptide it derives from, since the two are chemically related and a purity figure alone would not separate them. Those are the two analytical methods used, and no other method is claimed.
Each vial carries a batch number that resolves to the public Certificate of Analysis for its batch, reporting the compound, the lot reference, the HPLC result, the mass-spectrometry result, the analysis date, and the laboratory that ran it.
Compliance Notice
Research Use Only
Selank is catalogued strictly for in-vitro laboratory research. It is not for human consumption, veterinary use, or therapeutic, diagnostic or clinical application. It is not supplied as a medicinal product and it is not licensed by the MHRA.
Not a Medical Product
None of the compounds listed on this site are medicinal products, nor should they be marketed, described or used as such. No medical claims are made about Selank. Nothing on this page is medical, veterinary or scientific advice, and no guidance on preparation, administration or quantity is provided or will be provided on request.
Compliance and Responsibility
The research user is responsible for ensuring compliance with all laws and regulations governing the receipt, handling, storage, use and disposal of research chemicals in their jurisdiction, and for applying appropriate control measures under the Control of Substances Hazardous to Health Regulations 2002 or the equivalent local regime.
Analytical Scope
Analytical results published for Selank relate solely to the batch identified on the Certificate of Analysis. Two methods are used: high-performance liquid chromatography and mass spectrometry. No other analysis is performed or implied. Results for one batch do not warrant any other batch.
Jurisdiction Notice
Selank cannot be listed to research users in the following jurisdictions: Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. It is the research user's responsibility to verify local eligibility before placing an order. Where an order is placed for a jurisdiction in which the compound cannot be listed, the order will be cancelled and refunded in full.
§05Related compounds
§06Questions
No. Selank is catalogued strictly for in-vitro laboratory research. It is not for human or veterinary consumption and no medical claims are made.
GABA-A receptor subunit expression, inhibition of enkephalin-degrading enzymes, and neuroimmune signalling measures such as interleukin-6 and interferon-gamma expression.
Tuftsin, a tetrapeptide fragment of the immunoglobulin G heavy chain, extended at the C-terminus with Pro-Gly-Pro for stability. The full sequence is TKPRPGP.
Pre-mixed liquid in a sealed 3ml vial, at 10mg. No reconstitution is required.
HPLC for purity and mass spectrometry for identity, on every batch, before it is listed. Mass spectrometry also separates the heptapeptide from the tuftsin tetrapeptide it derives from. No further assay is claimed.
Every batch has a document.
The Certificate of Analysis for a batch is published when that batch is released. Your batch number resolves to the report.
For laboratory research only. Not for human consumption. No medical claims.
